glp 1 muscle loss and GLP-1R agonists use Balancing weight and muscle loss

A 2025 meta-analysis in JAMA Psychiatry looked at GLP-1 receptor agonists and mental health outcomes across multiple studies

See my before & after and learn what truly helped me transform

This blog is part of an ongoing series, A Brave New World: Therapeutic Area Deep Dives

Cigna will stop covering GLP-1 weight-loss drugs such as Wegovy and Zepbound for its employees starting July 1, signaling that even major healthcare companies are struggling with the high cost of these medications

These assets aim to move beyond the current weekly injection paradigm, signalling a future where extended dosing intervals could become central to maintenance strategies [16].